Cancer BiologybioRxivPreprint
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
A. J. Arribas, E. Gaudio, S. Napoli…·F. Bertoni
This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.
DOI 10.1101/2023.11.14.566994